4169 Taizong Signs Exclusive License Agreement with U.S. Subsidiary TCM Life Science Inc. for U101

Release Date: July 3, 2026 Statement Date: July 2, 2026 Statement Time: 16:14:40 Company Code: 4169 Company Name: Taizong

Subject: The Board of Directors has resolved to enter into an exclusive license agreement with its subsidiary, TCM Life Science Inc., regarding U101.

Applicable Clause: Clause 10 Event Date: July 2, 2026

Details: 1. Event Date: July 2, 2026 2. Contract Counterparty: TCM Life Science Inc. 3. Relationship with Company: TCM Life Science Inc. is a U.S.-incorporated subsidiary wholly owned (100%) by the Company. 4. Contract Period (or Termination Date): The agreement becomes effective upon receipt of funding or sublicense revenue by TCM Life Science Inc., as stipulated in the contract. The license term extends for the duration of patent validity or ten years post-approval in each region. 5. Main Content: Exclusive rights to U101 are granted to the U.S. subsidiary TCM Life Science Inc. for global clinical development, registration, manufacturing, and commercialization. The total contract value, including development and sales milestone payments, amounts to USD 750 million. 6. Restrictive Clauses: As specified in the contract. 7. Commitments: As specified in the contract. 8. Other Important Provisions: As specified in the contract. 9. Impact on Company's Financials and Operations: Facilitates international expansion of U101. 10. Specific Purpose: To enable the U.S. subsidiary to conduct global R&D (including Phase III clinical trials) and commercialization of U101 in global markets. 11. Additional Disclosure: The Board has authorized the Chairman to handle all necessary matters, documentation, and procedures related to this agreement as needed.